Skip to main content

Advertisement

SpringerLink
Log in

Cyclin E deregulation is an early event in the development of breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Cyclin E has been shown to be overexpressed in some human breast cancers, however, data to support deregulation of cyclin E as an early event in human mammary tumor development is lacking. We analyzed surgical specimens from 183 patients with breast carcinomas and evaluated cyclin E expression in areas of invasive carcinoma, adjacent carcinoma in situ (CIS), and non-neoplastic breast parenchyma. Overexpression of cyclin E was seen in one-third of invasive carcinoma samples, one-third of the CIS component and nearly half of the non-neoplastic breast epithelial cells adjacent to carcinoma (44% vs. 33%, P ≤ 0.05). Nuclear labeling for cyclin E was highly concordant between areas of in invasive carcinoma, CIS and non-neoplastic breast epithelial cells from the same patient (P < 0.0001). Localization of cyclin E to the cytoplasm was seen in a small proportion of tumor samples. Our findings suggest that cyclin E deregulation is an early event in the progression from histologically benign mammary epithelial cells to invasive carcinoma and occurs through both overexpression and altered cellular localization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677. doi:10.1126/science.274.5293.1672

    Article  PubMed  CAS  Google Scholar 

  2. Koff A, Giordano A, Desia D, Yamashita K, Harper J, Elledge S, Nishomoto T, Morgan D, Franza R, Roberts J (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689–1694. doi:10.1126/science.1388288

    Article  PubMed  CAS  Google Scholar 

  3. Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN (2005) Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 11(4):1447–1453. doi:10.1158/1078-0432.CCR-04-1730

    Article  PubMed  CAS  Google Scholar 

  4. Tissier F, Louvel A, Grabar S, Hagnere AM, Bertherat J, Vacher-Lavenu MC, Dousset B, Chapuis Y, Bertagna X, Gicquel C (2004) Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 150(6):809–817. doi:10.1530/eje.0.1500809

    Article  PubMed  CAS  Google Scholar 

  5. Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell’Oro S, Baldini L, Buffa R, Carboni N, Villa E et al (2001) Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin’s lymphoma. Int J Cancer 94(4):599–604. doi:10.1002/ijc.1509

    Article  PubMed  CAS  Google Scholar 

  6. Farley J, Smith LM, Darcy KM, Sobel E, O’Connor D, Henderson B, Morrison LE, Birrer MJ (2003) Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63(6):1235–1241

    PubMed  CAS  Google Scholar 

  7. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566–1575. doi:10.1056/NEJMoa021153

    Article  PubMed  CAS  Google Scholar 

  8. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3(2):222–225. doi:10.1038/nm0297-222

    Article  PubMed  CAS  Google Scholar 

  9. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H (2000) Prognostic significance of cyclin E overexpression in resected non- small cell lung cancer. Cancer Res 60(2):242–244

    PubMed  CAS  Google Scholar 

  10. Jang SJ, Park YW, Park MH, Lee JD, Lee YY, Jung TJ, Kim IS, Choi IY, Ki M, Choi BY et al (1999) Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol 25(2):157–163. doi:10.1053/ejso.1998.0619

    Article  PubMed  CAS  Google Scholar 

  11. Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, Shimizu M, Katoh H, Kawakami Y (2000) Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 6(1):11–16

    PubMed  CAS  Google Scholar 

  12. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J (2006) Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9):1925–1932. doi:10.1002/cncr.21767

    Article  PubMed  CAS  Google Scholar 

  13. Keyomarsi K, Pardee A (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112–1116. doi:10.1073/pnas.90.3.1112

    Article  PubMed  CAS  Google Scholar 

  14. Porter D, Zhang N, Danes C, McGrehan M, Harwell R, Farouk S, Keyomarsi K (2001) Tumor specific proteolytic processing of cyclin E generates hyper-active lower molecular weight forms. Mol Cell Biol 21:6254–6269. doi:10.1128/MCB.21.18.6254-6269.2001

    Article  PubMed  CAS  Google Scholar 

  15. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401(6750):297–300. doi:10.1038/45836

    Article  PubMed  CAS  Google Scholar 

  16. Bortner DM, Rosenberg MP (1997) Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17(1):453–459

    PubMed  CAS  Google Scholar 

  17. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64(9):3198–3208. doi:10.1158/0008-5472.CAN-03-3672

    Article  PubMed  CAS  Google Scholar 

  18. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864–870. doi:10.1038/nature03482

    Article  PubMed  CAS  Google Scholar 

  19. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J (2006) Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 66(21):10258–10263. doi:10.1158/0008-5472.CAN-06-2178

    Article  PubMed  CAS  Google Scholar 

  20. Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G (2003) Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer 89(10):1920–1926. doi:10.1038/sj.bjc.6601398

    Article  PubMed  CAS  Google Scholar 

  21. Scott KA, Walker RA (1997) Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer 76(10):1288–1292

    PubMed  CAS  Google Scholar 

  22. Donnellan R, Kleinschmidt I, Chetty R (2001) Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 32(1):89–94. doi:10.1053/hupa.2001.21141

    Article  PubMed  CAS  Google Scholar 

  23. Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C, de Bal Kier Joffe E, Puricelli L (2004) Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep 12(5):1143–1150

    PubMed  CAS  Google Scholar 

  24. Reed W, Sandstad B, Holm R, Nesland JM (2003) The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators. Int J Surg Pathol 11(2):65–74. doi:10.1177/106689690301100201

    Article  PubMed  CAS  Google Scholar 

  25. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83(4):241–247. doi:10.1002/jso.10268

    Article  PubMed  Google Scholar 

  26. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R (2005) Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69(6):478–485. doi:10.1159/000090986

    Article  PubMed  Google Scholar 

  27. Kim HK, Park IA, Heo DS, Noh DY, Choe KJ, Bang YJ, Kim NK (2001) Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur J Surg Oncol 27(5):464–471. doi:10.1053/ejso.2001.1137

    Article  PubMed  CAS  Google Scholar 

  28. Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD (2005) Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16(5):735–742. doi:10.1093/annonc/mdi149

    Article  PubMed  CAS  Google Scholar 

  29. Rao S, Lowe M, Herliczek T, Keyomarsi K (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393–2402. doi:10.1038/sj.onc.1202322

    Article  PubMed  CAS  Google Scholar 

  30. Nielsen NH, Arnerlov C, Emdin SO, Landberg G (1996) Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74(6):874–880

    PubMed  CAS  Google Scholar 

  31. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R (2006) Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25(1):59–64

    PubMed  CAS  Google Scholar 

  32. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15(5):2612–2624

    PubMed  CAS  Google Scholar 

  33. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E (1996) Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science 271:499–502. doi:10.1126/science.271.5248.499

    Article  PubMed  CAS  Google Scholar 

  34. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22(31):4898–4904. doi:10.1038/sj.onc.1206818

    Article  PubMed  CAS  Google Scholar 

  35. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212–7222. doi:10.1158/0008-5472.CAN-07-0599

    Article  PubMed  CAS  Google Scholar 

  36. Geng Y, Lee YM, Welcker M, Swanger J, Zagozdzon A, Winer JD, Roberts JM, Kaldis P, Clurman BE, Sicinski P (2007) Kinase-independent function of cyclin E. Mol Cell 25(1):127–139. doi:10.1016/j.molcel.2006.11.029

    Article  PubMed  CAS  Google Scholar 

  37. Jackman M, Kubota Y, den Elzen N, Hagting A, Pines J (2002) Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell 13(3):1030–1045. doi:10.1091/mbc.01-07-0361

    Article  PubMed  CAS  Google Scholar 

  38. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE et al (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103(1):127–140. doi:10.1016/S0092-8674(00)00093-3

    Article  PubMed  CAS  Google Scholar 

  39. Moore JD, Kornbluth S, Hunt T (2002) Identification of the nuclear localization signal in Xenopus cyclin E and analysis of its role in replication and mitosis. Mol Biol Cell 13(12):4388–4400. doi:10.1091/mbc.E02-07-0449

    Article  PubMed  CAS  Google Scholar 

  40. Furuno N, den Elzen N, Pines J (1999) Human cyclin A is required for mitosis until mid prophase. J Cell Biol 147(2):295–306. doi:10.1083/jcb.147.2.295

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Robyn Kuhn and Roland L. Bassett Jr. for their assistance with the statistical analysis. Supported by Texas Federation of Business and Professional Women and National Institutes of Health grant CA116199 (SPORE in Breast Cancer).

Author information

Authors and Affiliations

  1. Department of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

    Alexandra Shaye & Aysegul Sahin

  2. Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, P.O. Box 444, Houston, TX, 77030, USA

    Qiang Hao, Kelly Hunt, Khandan Keyomarsi & Isabelle Bedrosian

  3. Department of Experimental Radiation Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

    Kelly Hunt & Khandan Keyomarsi

Authors
  1. Alexandra Shaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysegul Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiang Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kelly Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khandan Keyomarsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isabelle Bedrosian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabelle Bedrosian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shaye, A., Sahin, A., Hao, Q. et al. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115, 651–659 (2009). https://doi.org/10.1007/s10549-008-0266-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0266-0

Keywords

Search

Navigation